Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 17

1.

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators.

N Engl J Med. 2012 Sep 20;367(12):1098-107. Erratum in: N Engl J Med. 2012 Dec 13;367(24):2362.

2.

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group.

Lancet Neurol. 2011 Jun;10(6):520-9. doi: 10.1016/S1474-4422(11)70099-0. Epub 2011 May 13.

PMID:
21571593
3.

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.

4.

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.

Pöhlau D, Przuntek H, Sailer M, Bethke F, Koehler J, König N, Heesen C, Späth P, Andresen I.

Mult Scler. 2007 Nov;13(9):1107-17. Epub 2007 Jul 10.

PMID:
17623736
5.

Long-term antibiotic treatment with roxithromycin in patients with multiple sclerosis.

Woessner R, Grauer MT, Frese A, Bethke F, Ginger T, Hans A, Treib J.

Infection. 2006 Dec;34(6):342-4.

PMID:
17180590
6.

Conducting without memory - a case report on transient global amnesia.

Evers S, Frese A, Bethke F.

Eur J Neurol. 2002 Nov;9(6):695-6. No abstract available.

PMID:
12453094
7.

Event-related potentials in different subtypes of multiple sclerosis--a cross-sectional study.

Ellger T, Bethke F, Frese A, Luettmann RJ, Buchheister A, Ringelstein EB, Evers S.

J Neurol Sci. 2002 Dec 15;205(1):35-40.

PMID:
12409181
8.

Therapy of Sneddon syndrome.

Flöel A, Imai T, Lohmann H, Bethke F, Sunderkötter C, Droste DW.

Eur Neurol. 2002;48(3):126-32.

PMID:
12373028
9.

Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.

Frese A, Bethke F, Lüdemann P, Stögbauer F.

J Neurol. 2000 Sep;247(9):713. No abstract available.

PMID:
11081814
10.

Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.

Frese A, Bethke F, Lüdemann P, Stögbauer F.

Neurology. 1999 Nov 10;53(8):1892-3. No abstract available.

PMID:
10563657
11.

Human herpesvirus 8 cellular immune responses in homosexual men.

Strickler HD, Goedert JJ, Bethke FR, Trubey CM, O'Brien TR, Palefsky J, Whitman JE, Ablashi D, Zeichner S, Shearer GM.

J Infect Dis. 1999 Nov;180(5):1682-5.

12.

Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis -- outline of a double-blind randomized, placebo-controlled trial.

Poehlau D, Federlein J, Postert T, Sailer M, Bethke F, Kappos L, Haas J, Przuntek H.

Mult Scler. 1997 Apr;3(2):149-52.

PMID:
9291171
13.

In vitro immunologic and virologic effects of interleukin 15 on peripheral blood mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients.

Lucey DR, Pinto LA, Bethke FR, Rusnak J, Melcher GP, Hashemi FN, Landay AL, Kessler HA, Paxton RJ, Grabstein K, Shearer GM.

Clin Diagn Lab Immunol. 1997 Jan;4(1):43-8.

14.

Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.

VanCott TC, Bethke FR, Burke DS, Redfield RR, Birx DL.

J Immunol. 1995 Oct 15;155(8):4100-10.

PMID:
7561123
15.

Preferential antibody recognition of structurally distinct HIV-1 gp120 molecules.

VanCott TC, Bethke FR, Kalyanaraman V, Burke DS, Redfield RR, Birx DL.

J Acquir Immune Defic Syndr. 1994 Nov;7(11):1103-15.

PMID:
7523653
16.

Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1.

VanCott TC, Bethke FR, Polonis VR, Gorny MK, Zolla-Pazner S, Redfield RR, Birx DL.

J Immunol. 1994 Jul 1;153(1):449-59.

PMID:
7515931
17.

Measurement of cerebrospinal fluid antibody to the HIV-1 principal neutralizing determinant (V3 loop).

Lucey DR, VanCott TC, Loomis LD, Bethke FR, Hendrix CW, Melcher GP, Redfield RR, Birx DL.

J Acquir Immune Defic Syndr. 1993 Sep;6(9):994-1001.

PMID:
7688046
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk